ArticleFrontiers in immunology2025
Efficacy prediction of systemic immune-inflammation index and prognostic nutritional index in breast cancer patients and their variations after neoadjuvant chemotherapy.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic value of the systemic immune-inflammation index in gastrointestinal cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Systematic Review and Meta-Analysis of AI-Assisted Mammography and the Systemic Immune-Inflammation Index in Breast Cancer: Diagnostic and Prognostic Perspectives.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.Journal of clinical medicine · 2026Article
- Article
- Impact of vitamin D deficiency and inflammatory biomarkers on pathological response to neoadjuvant chemotherapy in breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- PIV, PNI and HALP score for predicting pathological complete response in breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Article
- Dynamic systemic immune-inflammation index predicts survival after neoadjuvant immunotherapy in gastric cancer: A multicenter study.iScience · 2026Article
- Prognostic Value of Baseline Systemic Immune-Inflammation Index in Advanced Intrahepatic Cholangiocarcinoma Treated with First-Line Gemcitabine-Cisplatin Plus PD-L1 Inhibitor: A Single-Center Retrospective Study.Current oncology (Toronto, Ont.) · 2026Article
- Dynamic Immune-Nutritional Indices as Powerful Predictors of Pathological Complete Response in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.Journal of clinical medicine · 2026Article
- The prognostic value of lymphocyte-albumin-neutrophil ratio variability in patients with breast cancer undergoing radiotherapy.Frontiers in oncology · 2026Article
- Systemic nutritional status and its dynamic changes as predictors of response to neoadjuvant immunotherapy in locally advanced MSS/pMMR colorectal cancer.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose of this study was to evaluate the predictive values of systemic immune-inflammatory index (SII), prognostic nutrition index (PNI), change of SII (ΔSII), change of PNI (ΔPNI) and ΔPNI-ΔSII score in patients with neoadjuvant chemotherapy for breast cancer. Methods: We enrolled in a retrospective study involving 72 patients with breast cancer between February 2020 and January 2022. All patients had clinical features of axillary lymph node metastasis and received neoadjuvant therapy. PNI and SII were detected by hematology before and after treatment. Chi-square test was used to compare the clinicopathological and experimental parameters among all groups. Logistic regression analysis was used to evaluate the prognostic value of each factor. Results: The prognosis was evaluated and 18 patients (25%) achieved pathological complete response (pCR) after neoadjuvant therapy. The pCR rate of breast cancer patients was significantly correlated with ER, PR, HER-2, molecular subsets, tumor size, vascular invasion, nerve invasion, N stage, clinical stage and chemotherapy regimen. Low ΔPNI, high ΔSII and higher ΔPNI-ΔSII score values had better prediction of therapeutic effect, especially the ΔPNI-ΔSII score. Conclusion: In breast cancer patients receiving neoadjuvant chemotherapy, ΔPNI-ΔSII score is an effective predictor of efficacy, which helps to identify high-risk groups and evaluate efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.